Literature DB >> 10068652

Biallelic and heterozygous point mutations in the runt domain of the AML1/PEBP2alphaB gene associated with myeloblastic leukemias.

M Osato1, N Asou, E Abdalla, K Hoshino, H Yamasaki, T Okubo, H Suzushima, K Takatsuki, T Kanno, K Shigesada, Y Ito.   

Abstract

The AML1 gene encoding the DNA-binding alpha-subunit in the Runt domain family of heterodimeric transcription factors has been noted for its frequent involvement in chromosomal translocations associated with leukemia. Using reverse transcriptase-polymerase chain reaction (RT-PCR) combined with nonisotopic RNase cleavage assay (NIRCA), we found point mutations of the AML1 gene in 8 of 160 leukemia patients: silent mutations, heterozygous missense mutations, and biallelic nonsense or frameshift mutations in 2, 4, and 2 cases, respectively. The mutations were all clustered within the Runt domain. Missense mutations identified in 3 patients showed neither DNA binding nor transactivation, although being active in heterodimerization. These defective missense mutants may be relevant to the predisposition or progression of leukemia. On the other hand, the biallelic nonsense mutants encoding truncated AML1 proteins lost almost all functions examined and may play a role in leukemogenesis leading to acute myeloblastic leukemia.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10068652

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  99 in total

1.  Role for Hes1-induced phosphorylation in Groucho-mediated transcriptional repression.

Authors:  Hugh N Nuthall; Junaid Husain; Keith W McLarren; Stefano Stifani
Journal:  Mol Cell Biol       Date:  2002-01       Impact factor: 4.272

2.  Transcription factor mutations in myelodysplastic/myeloproliferative neoplasms.

Authors:  Thomas Ernst; Andrew Chase; Katerina Zoi; Katherine Waghorn; Claire Hidalgo-Curtis; Joannah Score; Amy Jones; Francis Grand; Andreas Reiter; Andreas Hochhaus; Nicholas C P Cross
Journal:  Haematologica       Date:  2010-04-26       Impact factor: 9.941

3.  The human SWI/SNF complex associates with RUNX1 to control transcription of hematopoietic target genes.

Authors:  Rachit Bakshi; Mohammad Q Hassan; Jitesh Pratap; Jane B Lian; Martin A Montecino; Andre J van Wijnen; Janet L Stein; Anthony N Imbalzano; Gary S Stein
Journal:  J Cell Physiol       Date:  2010-11       Impact factor: 6.384

4.  Biological characteristics of the leukemia-associated transcriptional factor AML1 disclosed by hematopoietic rescue of AML1-deficient embryonic stem cells by using a knock-in strategy.

Authors:  T Okuda; K Takeda; Y Fujita; M Nishimura; S Yagyu; M Yoshida; S Akira; J R Downing; T Abe
Journal:  Mol Cell Biol       Date:  2000-01       Impact factor: 4.272

5.  Runx2 induces acute myeloid leukemia in cooperation with Cbfbeta-SMMHC in mice.

Authors:  Ya-Huei Kuo; Sayyed K Zaidi; Svetlana Gornostaeva; Toshihisa Komori; Gary S Stein; Lucio H Castilla
Journal:  Blood       Date:  2009-01-28       Impact factor: 22.113

Review 6.  Cytogenetics in acute myeloid leukemia.

Authors:  Claudia Schoch; Torsten Haferlach
Journal:  Curr Oncol Rep       Date:  2002-09       Impact factor: 5.075

Review 7.  Runx1/AML1 in normal and abnormal hematopoiesis.

Authors:  Tetsuya Yamagata; Kazuhiro Maki; Kinuko Mitani
Journal:  Int J Hematol       Date:  2005-07       Impact factor: 2.490

8.  Stem cell exhaustion due to Runx1 deficiency is prevented by Evi5 activation in leukemogenesis.

Authors:  Bindya Jacob; Motomi Osato; Namiko Yamashita; Chelsia Qiuxia Wang; Ichiro Taniuchi; Dan R Littman; Norio Asou; Yoshiaki Ito
Journal:  Blood       Date:  2009-12-14       Impact factor: 22.113

9.  Gene array analysis reveals a common Runx transcriptional programme controlling cell adhesion and survival.

Authors:  S Wotton; A Terry; A Kilbey; A Jenkins; P Herzyk; E Cameron; J C Neil
Journal:  Oncogene       Date:  2008-06-16       Impact factor: 9.867

10.  RUNX1 mutations enhance self-renewal and block granulocytic differentiation in human in vitro models and primary AMLs.

Authors:  Mylène Gerritsen; Guoqiang Yi; Esther Tijchon; Jorren Kuster; Jan Jacob Schuringa; Joost H A Martens; Edo Vellenga
Journal:  Blood Adv       Date:  2019-02-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.